Business Wire

DC-GALLUP

25.6.2024 06:02:29 CEST | Business Wire | Press release

Share
Negative Emotions High Across Countries in Conflict in Greater Europe

In 2023, Ukraine was engulfed in war, while a new clash erupted between Israel and Hamas in the European sphere of influence. The Gallup Global Emotions 2024 report reveals the emotional toll of these conflicts.

The report offers a snapshot of Gallup’s latest measurements of people’s positive and negative daily experiences. The findings are based on nearly 146,000 interviews with adults in 142 countries and areas in 2023. While global negative emotions dipped for the first time in a decade and positive emotions rebounded to their pre-pandemic highs, many of the world’s conflict zones remained bleak.

After Oct. 7 Attacks, Israel Vaulted to Top 10 in Negative Emotions

Israel, surveyed by Gallup two weeks after the Oct. 7 Hamas attacks, made the top 10 list of countries with the worst Negative Experience Index scores for the first time, at 47. In 2022, Israel ranked among the countries with the lowest scores in the world on this index.

Fueling this low score, Israelis saw massive increases in feelings of sadness (up 39 percentage points to 51%), stress (up 38 points to 62%), anger (up 23 points to 36%) and worry (up 37 points to 67%).

Ukrainian Negative Emotions Remained at Post-Invasion Record Highs

As Ukraine continued to fend off Russian offensives within its borders in 2023, Ukrainians reported record-tying levels of sadness (39%), stress (32%), anger (22%) and worry (53%).

Negative Emotions Dropped in Azerbaijan After Ceasefire

Following the signing of the Nagorno-Karabakh ceasefire agreement, Azerbaijan led the world in declining stress levels — dropping from 40% to 14% in the span of a year. In addition to less stress, Azerbaijanis reported significant decreases in feelings of daily anger, worry and sadness.

About the Indexes

Gallup’s Positive and Negative Experience Indexes measure life’s intangibles — feelings and emotions — that traditional economic indicators such as GDP were never intended to capture. Each index provides a real-time snapshot of people’s daily experiences, offering leaders insights into the health of their societies that they cannot gather from economic measures alone.

Negative Experience Index Dipped in 2023

On a global level, Gallup’s Negative Experience Index declined for the first time since 2014. All five negative emotions that make up the index fell between 2022 and 2023, but stress levels dropped the most. Thirty-seven percent of the world felt stressed in 2023, down three points from the previous year but well above where it was a decade ago (33%) and the years before that.

Positive Experience Index Rebounded Post-Pandemic

Further reinforcing that 2023 was a better year for the world’s emotional health, positive experiences rebounded to their pre-pandemic levels, completing the recovery that started in 2022.

People younger than 30 continued to be the most positive of all age groups. Further, their positivity rebounded faster, with emotions bouncing back a year earlier than their older peers. Most of the improvement on the index in 2023 took place among those aged 30 and older.

About Gallup

Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.

About the Gallup World Poll

The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 99% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries. The Gallup World Poll is used to measure and track progress on several U.N. sustainable development goals and is the official statistic for work and life for more than 55 indexes and metrics associated with the most important aspects of individuals’ lives, their communities and their countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624491362/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye